HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (18) Citing Articles via Google Scholar Google Scholar Articles by Guenoun, J.-M. Articles by Brignole-Baudouin, F. Search for Related Content PubMed PubMed Citation Articles by Guenoun, J.-M. Articles by Brignole-Baudouin, F.

In Vitro Study of Inflammatory Potential and Toxicity Profile of Latanoprost, Travoprost, and Bimatoprost in Conjunctiva-Derived Epithelial Cells

¹From the Department of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital, Paris, France; the ²Department of Ophthalmology, Ambroise Paré Hospital, Paris Ile-de-France Ouest School of Medicine, University of Versailles, Paris, France; the ³Department of Toxicology, Faculty of Biological and Pharmacological Sciences, René Descartes University Paris 5, Paris, France; and ⁴Institut National de la Santé et de la Recherche Médicale, U598, Cordeliers Biomedical Institute, Paris, France.

PURPOSE. Conjunctiva-derived epithelial cells were used to investigate, in vitro, the expression of various inflammation-associated markers known to be overexpressed in patients with glaucoma after contact with the three major commercially available eye drops containing prostaglandin analogues. The impact on cellular viability and apoptosis in the same cell line was evaluated, to address the possible proinflammatory and/or toxic origin of the most frequent clinical impairments induced by prostanoids (i.e., conjunctival hyperemia).

METHODS. Conjunctiva-derived cells were treated in vitro with the commercial solutions of latanoprost, travoprost, bimatoprost, prostaglandin (PG)F2, tumor necrosis factor (TNF)-, and different concentrations of benzalkonium chloride (BAC). Expressions of three inflammation- and immune-related markers, intercellular adhesion molecule (ICAM)-1, platelet-endothelial cell adhesion molecule (PECAM)-1 and HLA DR, were evaluated with flow cytometry after 24 to 72 hours of contact at low, subtoxic concentrations. Toxicological tests were also performed with cold-light cytofluorometry, in which cellular viability and apoptosis were evaluated with the neutral red and Hoechst/propidium iodide tests, respectively.

RESULTS. TNF induced or stimulated expression of the three inflammatory markers, whereas the PGF2, latanoprost, travoprost, and bimatoprost solutions did not induce an increase in these markers and even produced a marked reduction of ICAM-1 and PECAM-1 expression in those solutions most concentrated in BAC, thus suggesting a toxic phenomenon in cellular membranes induced by the preservative rather than the medication itself. Cytotoxic assays confirmed this hypothesis and showed significant toxicity with prostaglandin analogues after prolonged contact, proportional to the concentration of BAC in the solution and similar to that of the corresponding concentration of BAC alone, bimatoprost having both the least concentration of BAC and the least cytotoxic in these experimental conditions.

CONCLUSIONS. The comparison of latanoprost, travoprost, and bimatoprost, in their commercial formulations, showed that none of them appeared to induce direct stimulation of the inflammatory pathways involving adhesion molecules or class II antigens, although these markers have been found ex vivo in conjunctival specimens from patients treated with prostaglandins. In fact, their toxicity was mild and seemed to be primarily related to the concentration of BAC, their common preservative, which may be the major factor responsible for long-term ocular surface reactions in patients receiving topical prostaglandins, but most likely is not a factor in early and transient conjunctival hyperemia.

This article has been cited by other articles:

				H Liang, C Baudouin, A Pauly, and F Brignole-Baudouin Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride Br. J. Ophthalmol., September 1, 2008; 92(9): 1275 - 1282. [Abstract] [Full Text] [PDF]

				A. Pauly, F. Brignole-Baudouin, A. Labbe, H. Liang, J.-M. Warnet, and C. Baudouin New Tools for the Evaluation of Toxic Ocular Surface Changes in the Rat Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5473 - 5483. [Abstract] [Full Text] [PDF]

				C. Baudouin, L. Riancho, J.-M. Warnet, and F. Brignole In Vitro Studies of Antiglaucomatous Prostaglandin Analogues: Travoprost with and without Benzalkonium Chloride and Preserved Latanoprost Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4123 - 4128. [Abstract] [Full Text] [PDF]

				L Malvitte, T Montange, A Vejux, C Baudouin, A M Bron, C Creuzot-Garcher, and G Lizard Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs Br. J. Ophthalmol., January 1, 2007; 91(1): 29 - 32. [Abstract] [Full Text] [PDF]

				J.-M. Guenoun, C. Baudouin, P. Rat, A. Pauly, J.-M. Warnet, and F. Brignole-Baudouin In Vitro Comparison of Cytoprotective and Antioxidative Effects of Latanoprost, Travoprost, and Bimatoprost on Conjunctiva-Derived Epithelial Cells Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4594 - 4599. [Abstract] [Full Text] [PDF]